Caraco Pharmaceutical Laboratories, Ltd. Markets Nicardipine Hydrochloride Injection

Share Name	Share Symbol	Market	Type
Caraco Pharmaceutical Laboratories, Ltd. Common Stock	AMEX:CPD	AMEX	Ordinary Share

Share Name

Share Symbol

Market

Type

Caraco Pharmaceutical Laboratories, Ltd. Common Stock

AMEX:CPD

AMEX

Ordinary Share

Price Change

% Change

Share Price

High Price

Low Price

Open Price

Shares Traded

Last Trade

0.00

0.00%

0.00

Caraco Pharmaceutical Laboratories, Ltd. Markets Nicardipine Hydrochloride Injection

18/11/2009 3:20pm

PR Newswire (US)

Caraco (AMEX:CPD)
Historical Stock Chart

From Jun 2019 to Jun 2024

DETROIT, Nov. 18 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD) has launched Nicardipine Hydrochloride Injection immediately following Sun Pharma's final approval from the US Food and Drug Administration (FDA). Nicardipine Hydrochloride Injection is indicated for the short-term treatment of hypertension when oral therapy is not feasible or not desirable. These Nicardipine Hydrochloride Injections are available as 25 mg/10ml single use ampuls containing 2.5 mg/ml of the drug, and have annual sales of approximately USD 170 million in the US. Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures, markets and distributes generic pharmaceuticals to the nation's largest wholesalers, distributors, drugstore chains and managed care providers. Safe Harbor: This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Without limitation, the words "believe" or "expect" and similar expressions are intended to identify forward-looking statements. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties are contained in the Corporation's filings with the Securities and Exchange Commission, including Part I, Item 1A of our most recent Form 10-K, and include but are not limited to: information of a preliminary nature that may be subject to adjustment, potentially not obtaining or delay in obtaining FDA approval for new products, governmental restrictions on the sale of certain products, development by competitors of new or superior products or less expensive products or new technology for the production of products, the entry into the market of new competitors, market and customer acceptance and demand for new pharmaceutical products, availability of raw materials, timing and success of product development and launches, dependence on few products generating majority of sales, product liability claims for which the Company may be inadequately insured, material litigation from product recalls, the purported class action lawsuits alleging federal securities laws violations, delays in returning the Company's products to market, including loss of market share, increased reserves against the FDA-seized inventory, and other risks identified in this report and from time to time in our periodic reports and registration statements. These forward-looking statements represent our judgment as of the date of this report. We disclaim, however, any intent or obligation to update our forward-looking statements. DATASOURCE: Caraco Pharmaceutical Laboratories, Ltd. CONTACT: Jitendra Doshi, +1-313-556-4104, or Thomas Versosky, +1-313-556-4150, both of Caraco Pharmaceutical Web Site: http://www.caraco.com/

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

CPD Caraco Pharmaceutical Laboratories, Ltd. Common Stock